For the third quarter of 2026, OnKure Therapeutics is expected to report a consensus EPS loss of $0.29 on zero revenue, with its current $18.25 share price trading at a sharp discount to the $32.00 analyst price target.
Investors are primarily focused on the clinical development progress of OKI-219, the company’s lead PI3Kα-selective inhibitor for breast cancer.
Following its 2024 merger with Reneo Pharmaceuticals, the firm is leveraging a $120 million cash runway to achieve key data readouts through 2026. This report will be scrutinized for updates on enrollment timelines and any shifts in the anticipated mid-2026 data milestones for its oncology pipeline.